Combination therapy: Future directions of immunotherapy in small cell lung cancer
Small cell lung cancer (SCLC), an aggressive and devastating malignancy, is characterized by rapid growth and early metastasis. Although most patients respond to first-line chemotherapy, the majority of patients rapidly relapse and have a relatively poor prognosis. Fortunately, immunotherapy, mainly...
Main Authors: | Wei Huang, Jia-Jia Chen, Rui Xing, Yue-Can Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523320303818 |
Similar Items
-
Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
by: Selina K. Wong, et al.
Published: (2021-01-01) -
Review on the Combination Strategy of Anti-angiogenic Agents
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer
by: Ziyi XU, et al.
Published: (2021-05-01) -
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
by: Masahiro Kagabu, et al.
Published: (2020-03-01) -
Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer
by: Hanfei GUO, et al.
Published: (2020-02-01) -
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
by: A. Pavan, et al.
Published: (2019-08-01)